miRNA-142-3p functions as a potential tumor suppressor directly targeting FAM83D in the development of ovarian cancer

Guangyu Gao1,*, Xiaofei Guo2,*, Wenyong Gu2,*, Yufeng Lu1, Zhigang Chen1

1Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
2Department of Ultrasound, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China
*Equal contribution

Correspondence to: Yufeng Lu, Zhigang Chen; email: luyufeng-011@163.com, 20185233105@stu.suda.edu.cn
Keywords: microRNA-142-3p, ovarian cancer, GEO, FAM83D, IHC
Received: January 19, 2022 Accepted: March 26, 2022 Published: April 22, 2022

ABSTRACT

Background: FAM83D (family with sequence similarity 83, member D) is of particular interest in tumorigenesis and tumor progression. Ovarian cancer is the leading cause of cancer-related death in women all over the world. This study aims to research the association between FAM83D and ovarian cancer (OC).

Methods: The gene expression data of OC and normal samples (GSE81873 and GSE27651) was downloaded from Gene Expression Omnibus (GEO) dataset. The bioinformatics analysis was performed to distinguish two differentially expressed genes (DEGs), prognostic candidate genes and functional enrichment pathways. Immunohistochemistry (IHC), Quantitative Real-time PCR (qPCR), and luciferase reporter assays were utilized for further study.

Results: There were 56 DEMs and 63 DEGs in cancer tissues compared to normal tissues. According to the kmplot software, hsa-miR-142-3p and FAM83D were associated with the overall survival of patients with OC. Besides, Multivariate analysis included that hsa-miR-142-3p and FAM83D were independent risk factors for OC patients. Furthermore, qPCR demonstrated that miRNA-142-3p and FAM83D were differentially expressed in normal ovarian tissues (NOTs) and ovarian cancer tissues (OCTs). IHC results indicated that FAM83D was overexpressed in OCTs compared with NOTs. Last but not least, luciferase reporter assays verified that FAM83D was a direct target of hsa-miRNA-142-3p in OC cells.

Conclusions: The prognostic model based on the miRNA-mRNA network could provide predictive significance for the prognosis of OC patients, which would be worthy of clinical application. Our results concluded that miR-142-3p and its targets gene FAM83D may be potential diagnostic and prognostic biomarkers for patients with OC.

INTRODUCTION

Ovarian cancer (OC) is one of the main causes of female death. 70% of patients are in the advanced stage (clinical stage III ~ IV), and peritoneal metastasis is the characteristic metastasis symptom of patients with advanced OC. Although the incidence rate is not high, the mortality rate is 2.9%, which is the top ten of female malignant tumor mortality. For OC, the current standard treatment is not optimistic [1]. One reason is that most patients are diagnosed only in the late stage of the disease. Standard treatment for OC usually includes surgery and platinum chemotherapy. Despite available treatments, the recurrence rate of OC is still high, and about 75% of advanced patients are incurable [2, 3]. Genomics research shows that there is no regulated gene mutation, and many clinical trials have failed to bring lasting clinical benefits [4]. Molecular typing of OC
through molecular expression differences, exploring the microenvironment characteristics of different molecular subtypes of OC, and formulating accurate treatment may be a feasible strategy to improve the dilemma of OC treatment.

Since the discovery of lin-4 and let-7, the founding members of the microRNA (miRNA) family, hundreds of miRNAs have been found in viruses, plants, and animals by molecular cloning and bioinformatics methods [5]. There are more than 1000 known human miRNAs, which control more than 50% of mammalian protein-coding genes. MiRNAs can be overexpressed or inhibited in different diseases. It is a promising therapeutic research field to inhibit or replace microRNAs [6]. Although microRNA has only 20 nucleotides, it plays a key role in biological function by targeting plenty of mRNAs [7]. For example, one study found that miRNA-424-5p regulated ferroptosis by targeting Acyl-CoA Synthetase Long-Chain Family Member 4 in OC cells and indicated a potential therapeutic target for OC [8]. Wu et al. found that the downregulated microRNA-1301-3p inhibited lung carcinoma cell proliferation and migration and has a strong negative correlation with Polymerase I and transcript release factor [9]. Another study also indicated the expression level of miR-200-b control PD-L1 expression in lung carcinoma cells. Furthermore, it may function as a potential biomarker for PD-L1 expression in lung cancer patients [10]. These studies indicated that microRNAs may be related to the progression of cancer, and their mechanisms may take part in the pathogenesis of tumors via controlling cancer-associated genes.

In this article, DEGs and DEMs were selected by researching 1 OC mRNA microarray dataset and 1 miRNA dataset. We aimed to study the relationship between miR-142-3p, FAM83D (we identified), and the development of OC.

**RESULTS**

**Identification of DEGs**

We used GEO2R to analysis the DEMs and DEGs from the GSE81873 and GSE27651. Based on the cut-off criteria, 56 DEMs such as hsa-microRNA-142-3p, hsa-microRNA-429, hsa-microRNA-199a-3p, hsa-microRNA-484, hsa-microRNA-139-5p, hsa-microRNA-483-5p, hsa-microRNA-423-5p, hsa-microRNA-342-3p, hsa-microRNA-885-5p, and 63 DEGs were selected (Figure 1).

**Gene ontology enrichment analysis**

By utilizing FunRich and R software, we performed TF enrichment analysis (Figure 2A).

KEGG and GO function enrichment analyses were performed here. As for GO function analysis, three GO were selected: molecular function (MF), cellular component (CC), and biological process (BP). Expression analysis showed that DEGs had the most uniquely enriched terms for Cell communication, Signal transduction, Regulation of nucleobase, nucleotide and nucleic acid metabolism, Cytoplasm, Nucleus, Cytosol, Membrane, Transcription factor activity, GTPase activity, Receptor signaling complex scaffold activity, Receptor signaling protein serine/threonine kinase activity, and CAMP-mediated signaling (Figure 2B–2D). Besides, DEMs were mainly enriched in 6 pathways: MAPK signaling pathway, PI3K-Akt signaling pathway, Wnt signaling pathway, TGF-beta signaling pathway, Pathways in cancer, and Bacterial invasion of epithelial cells (Figure 3A).

**miRNA-mRNA regulatory network**

According to FunRich software, 1069 potential target mRNAs were obtained and only 1 of them showed different expression levels in GSE27651 (FAM83D). Based on the association between them, 1 essential microRNA-mRNA pair (microRNA-142-3p and FAM83D) was selected for the next research (Figure 3B, 3C).

**genes expression and their associations with OC overall survival**

KM Plot was used to analyze the overall survival of patients with OC. According to uploading the miRNA and target gene we identified, we downloaded survival curves. The pictures showed that microRNA-124-3p and FAM83D were associated with the overall survival of patients with OC (Figure 4).

**Relationship between clinical characteristics and genes expression level of OC**

Clinical and gene expression information of OC patients were downloaded in the TCGA database, such as patients’ age, race, FIGO stage, and primary therapy outcome (Tables 1, 2). FAM83D and miR-142-3p expression of patients with Stage III and Stage IV was higher than that of patients with Stage I and Stage II (P<0.05) according to the FIGO stage. Furthermore, associations between clinical characteristics and overall survival in OC were analyzed. According to medium FAM83D and miR-142-3p expression, patients were divided into two groups. Our results indicated that FAM83D mRNA and miR-142-3p expression level (P<0.05), FIGO stage (P<0.05), Primary therapy outcome (P<0.05), and tumor stage (P<0.05) was related to the OS of patients with OC (Tables 3, 4).
Validation of the expression with qRT-PCR and IHC

To deeply evaluate the expression of miR-142-3p and FAM83D, 20 pairs of normal ovarian tissues (NOT) and OC tissues (OCT) were enrolled as a validation cohort. The qRT-PCR approach was utilized to verify the differential expression levels from the patient’s tissues. The same as the microarray data, hsa-miR-142-3p was significantly downregulated (Figure 5A) and FAM83D was overexpressed (Figure 5B) between 20 pairs of NOTs and OCTs which indicated that hsa-miR-142-3p and FAM83D could be the candidate biomarkers for OC. Besides, this expression level of genes was detected by IHC. The staining intensity of FAM83D was divided into 0, 1, 2, or 3, corresponding to colorless, light yellow, light brown, and squid ink. In addition, the percentage score is defined as: 0% to 5%, 0; 6% - 25%, 1 point; 26-50%, 2 points; 50-75%, 3 points; 76% to 100%, 4 points. The final histochemical score was calculated by multiplying the intensity score by the percentage score. The final staining scores were negative (0), low (6), and strong (≥ 6). Statistically, the overall expression of FAM83D was much higher in OC tissues than in the adjacent noncancerous tissues (P < 0.001) (Figure 5C–5F).

Figure 1. Heat map and volcano map of differentially expressed genes of GSE81873 and GSE27651. (A). Heat map of DEGs in GSE81873. (B). Volcano map of DEGs in GSE81873. (C). Heat map of DEGs in GSE27651. (D). Volcano map of DEGs in GSE27651. Red dots represent up-regulated genes and blue or green dots represent down-regulated genes.
Confirmation of the association between miR-142-3p and FAM83D

The Dual-Luciferase Reporter Assay System was utilized to evaluate the association between FAM83D and microRNA-142-3p. The FAM83D-WT activity of wild-type luciferase was 36.40%, and the FAM83D-MUT activity of mutant luciferase was 72.80%. These outcomes indicated that microRNA-142-3p reduced the luciferase activity of the wild-type FAM83D reporter gene (Figure 6).

DISCUSSION

In 2020, there were 19.29 million new cancer cases worldwide, including 10.06 million males and 9.23 million females; In 2020, there were 9.96 million cancer deaths worldwide, including 5.53 million males and 4.43 million females [11, 12]. In this research, GSE81873 and GSE27651 were obtained in the GEO database. 56 DEMs and 63 DEGs were identified. For deeply understanding the process of the 56 DEMs in OC, FunRich and R software were utilized for further study. GO and KEGG analysis indicated that these DEMs were primarily associated with the Cytoplasm, Nucleus, and Transcription factor activity. Previous studies have shown that Lysosomes and Nucleus may function as a vital role in plenty of human diseases, such as tumors, obesity, and infection [13–15]. Furthermore, KEGG analysis showed that DEGs were mainly enriched in 6 pathways such as MAPK signaling pathway, PI3K-Akt signaling pathway, Wnt signaling pathway, TGF-beta

Figure 2. Gene ontology enrichment. (A). Identification of the potential transcription factors of DEMs by FunRich software. (B) biological process, (C) cellular component, and (D) molecular function enrichment analysis of the DEMs.
signaling pathway, Pathways in cancer, and Bacterial invasion of epithelial cells, which were indicated to influence migration and proliferation [16]. The MAPK signaling pathway is a common signaling pathway closely associated with carcinoma, which will not be discussed here. Phosphatidylinositol-4,5-diphosphate-3-kinase (PI3K) is activated by many genes. In PI3K / Akt signal transduction pathway, phospholipid dependent kinase promotes the binding of protein kinase B (Akt) to the cell membrane. The phosphorylation of threonine

Figure 3. (A). KEGG pathway enrichment analysis of potential target mRNAs. (B). Venn Diagram of GSE81873 and GSE27651. (C). Identified target mRNAs and miRNA-mRNA regulatory network.

Figure 4. The association between the expression level of selected genes and overall survival of OC patients.
Table 1. Relationship between the expression level of FAM83D and clinical characteristics in OC.

| Characteristic                     | Low expression of FAM83D | High expression of FAM83D | p    |
|------------------------------------|--------------------------|---------------------------|------|
| n                                  | 189                      | 190                       |      |
| FIGO stage, n (%)                  |                          |                           | 0.007|
| Stage I                            | 0 (0%)                   | 1 (0.3%)                  |      |
| Stage II                           | 53 (13.9%)               | 10 (2.7%)                 |      |
| Stage III                          | 100 (26.3%)              | 155 (41.2%)               |      |
| Stage IV                           | 35 (9.3%)                | 22 (5.9%)                 |      |
| Primary therapy outcome, n (%)     |                          |                           | 0.484|
| PD                                 | 12 (3.9%)                | 15 (4.9%)                 |      |
| SD                                 | 14 (4.5%)                | 8 (2.6%)                  |      |
| PR                                 | 22 (7.1%)                | 21 (6.8%)                 |      |
| CR                                 | 102 (33.1%)              | 114 (37%)                 |      |
| Race, n (%)                        |                          |                           | 0.840|
| Asian                              | 5 (1.4%)                 | 7 (1.9%)                  |      |
| Black or African American          | 13 (3.6%)                | 12 (3.3%)                 |      |
| White                              | 161 (44.1%)              | 167 (45.8%)               |      |
| Age, n (%)                         |                          |                           | 0.383|
| <=60                               | 99 (26.1%)               | 109 (28.8%)               |      |
| >60                                | 90 (23.7%)               | 81 (21.4%)                |      |
| Age, median (IQR)                  | 60 (52, 68)              | 58 (50, 68)               | 0.390|

Table 2. Relationship between the expression level of hsa-miR-142-3p and clinical characteristics in OC.

| Characteristic                     | Low expression of hsa-miR-142-3p | High expression of hsa-miR-142-3p | p    |
|------------------------------------|----------------------------------|-----------------------------------|------|
| n                                  | 248                              | 248                               |      |
| FIGO stage, n (%)                  |                                  |                                   | 0.009|
| Stage I                            | 0 (0%)                           | 1 (0.2%)                          |      |
| Stage II                           | 13 (2.6%)                        | 76 (15.3%)                        |      |
| Stage III                          | 199 (40.4%)                      | 123 (24.8%)                       |      |
| Stage IV                           | 35 (7.1%)                        | 45 (9.1%)                         |      |
| Primary therapy outcome, n (%)     |                                  |                                   | 0.210|
| PD                                 | 21 (5.1%)                        | 15 (3.7%)                         |      |
| SD                                 | 16 (3.9%)                        | 9 (2.2%)                          |      |
| PR                                 | 24 (5.9%)                        | 32 (7.8%)                         |      |
| CR                                 | 139 (34.1%)                      | 152 (37.3%)                       |      |
| Race, n (%)                        |                                  |                                   | 0.472|
| Asian                              | 10 (2.1%)                        | 6 (1.3%)                          |      |
| Black or African American          | 14 (2.9%)                        | 18 (3.8%)                         |      |
| White                              | 215 (44.9%)                      | 216 (45.1%)                       |      |
| Age, n (%)                         |                                  |                                   | 0.786|
| <=60                               | 139 (28%)                        | 135 (27.2%)                       |      |
| >60                                | 109 (22%)                        | 113 (22.8%)                       |      |
| Age, median (IQR)                  | 58.5 (51, 69)                    | 59 (51.75, 68.25)                 | 0.873|
Table 3. Relationship between overall survival and the expression level of FAM83D researched by univariate and multivariate Cox regression.

| Characteristics      | Total(N) | Univariate analysis | Multivariate analysis |
|----------------------|----------|---------------------|-----------------------|
| FIGO stage           |          |                     |                       |
| Stage I & Stage II   | 24       | Reference           |                       |
| Stage III            | 293      | 2.045 (0.905-4.621) | 1.850 (0.670-5.108)   |
| Stage IV             | 57       | 2.495 (1.057-5.889) | 2.563 (1.541-4.517)   |
| Primary therapy outcome |        |                     |                       |
| PD                   | 27       | Reference           |                       |
| SD                   | 22       | 0.441 (0.217-0.895) | 0.463 (0.222-0.967)   |
| PR                   | 42       | 0.652 (0.384-1.107) | 0.637 (0.360-1.126)   |
| CR                   | 216      | 0.152 (0.093-0.247) | 0.203 (0.120-0.344)   |
| Race                 |          |                     |                       |
| Asian & Black or African American | 37 | Reference           |                       |
| White                | 327      | 0.637 (0.405-1.004) | 0.738 (0.434-1.255)   |
| FAM83D               | 377      | 1.645 (1.916-3.192) |                       |
| Tumor status         | 336      |                     |                       |
| Tumor free           | 72       | Reference           |                       |
| With tumor           | 264      | 9.576 (4.476-20.486)| 9.616 (3.875-23.866)  |

Table 4. Relationship between overall survival and the expression level of hsa-miR-142-3p researched by univariate and multivariate Cox regression.

| Characteristics      | Total(N) | Univariate analysis | Multivariate analysis |
|----------------------|----------|---------------------|-----------------------|
| FIGO stage           |          |                     |                       |
| Stage I & Stage II   | 30       | Reference           |                       |
| Stage III            | 380      | 2.179 (1.076-4.411) | 1.513 (1.664-3.446)   |
| Stage IV             | 80       | 2.785 (1.331-5.829) | 1.333 (1.563-3.155)   |
| Primary therapy outcome |      |                     |                       |
| PD                   | 36       | Reference           |                       |
| SD                   | 25       | 0.453 (0.241-0.854) | 0.452 (0.237-0.862)   |
| PR                   | 55       | 0.668 (0.426-1.047) | 0.635 (0.400-1.010)   |
| CR                   | 291      | 0.168 (0.112-0.251) | 0.211 (0.139-0.319)   |
| Race                 |          |                     |                       |
| Asian & Black or African American | 48 | Reference           |                       |
| White                | 430      | 0.764 (0.513-1.138) | 1.910 (1.783-2.458)   |
| hsa-miR-342-3p       | 494      | 0.835 (0.738-0.946) |                       |
| Tumor status         | 442      |                     |                       |
| Tumor free           | 95       | Reference           |                       |
| With tumor           | 347      | 8.796 (4.784-16.170)| 8.362 (4.057-17.236)  |

and serine promotes the transfer of Akt from the cytoplasm to the nucleus and further mediates the biological effects of enzymes, including cell proliferation, inhibition of apoptosis, cell migration, vesicle transport, and cell carcinogenesis [17]. Besides, it can influence the epithelial-mesenchymal transition in plenty of methods to affect tumor aggressiveness [18]. As for OC, a previous study reported that it took an important part in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors [19]. Neurotrophins are produced by target tissues innervated
by developing neurons, so these factors act on the end of axons and produce signals that must be transmitted back to the cell body [20]. It can activate the PI3K/Akt signal transduction pathway and other oncogenic signaling pathways [21]. For example, it has been confirmed that in the early stage of cancer, the increase of nerve density is parallel to the increase of neurotrophin level, but it remains to be clarified which cells in TME are the source of neurotrophin and the nature of the stimulants that initiate the production of neurotrophin [22]. Besides, a previous study reported that Neurotrophin Receptor TrkB (NTRK2) and Wnt β-Estradiol and MAPK signaling pathways are closely related to the worse prognosis of neuroblastoma [23]. Besides, the changes in neurotrophin signals are related to neurodegenerative diseases and mental diseases [24].

The regulated network was performed according to Cytoscape. 56 miRNAs (hsa-microRNA-142-3p, hsa-microRNA-429, hsa-microRNA-199a-3p, and hsa-microRNA-484) were selected for further research. After that, 1069 target genes were achieved and 1 of them

Figure 5. The expression level of hsa-miR-142-3p and FAM83D in normal ovarian tissues (NOTs) and OC tissues (OCTs). (A). Validation of hsa-miR-142-3p (***, p < 0.001). (B). Validation of FAM83D (***, p < 0.001). (C, D). The expression level of FAM83D in human OCTs. (E, F). The expression level of FAM83D in human NOTs (scale bar: 200×).

Figure 6. FAM83D is a direct target of miR-142-3p in OC cells. (A) Putative binding sites in FAM83D 3’UTR for miR-142-3p were predicted by bioinformatics analysis (microRNA.org). (B). Validation of luc2/luc-neo between miR-142-3p and FAM83D.
showed a different expression level in GSE27651 (FAM83D). MicroRNA-142-3p encoding human chromosome 17q22 is a new tumor suppressor factor, which is observed in many tumors including breast carcinoma, hepatocellular carcinoma, bladder carcinoma, and ovarian carcinoma [25–30]. The downregulation of microRNA-142-3p is related to tumorigenesis via regulation, cell migration, cell apoptosis, and invasion through various signaling pathways. Besides, microRNA-142-3p has been found as a carcinogenic microRNA in human T-cell acute lymphoblastic leukemia by acting on glucocorticoid receptors and cyclic adenosine monophosphate/protein kinase A pathway [31]. Upregulated microRNA-142-3p also monitors the characteristics of breast carcinoma stem cells, at least in section by sensitizing the WNT signaling pathway and microRNA-150 expression [32]. A previous study reported that upregulated microRNA-142-3p inhibited colorectal cancer cell migration and invasion, indicating that microRNA-142-3p may act as an oncogene during colorectal cancer tumorigenesis [33]. As for OC, another study concluded that microRNA-142-3p suppressed the proliferation and chemoresistance of OC cells by targeting SIRT1. This indicates that microRNA-142-3p may be a therapeutic target for the cure of OC [27].

FAM83D (family with sequence similarity 83, member D) is a mitosis-related gene located on chromosome 20q11 [34]. Previous studies have indicated that FAM83D may be amplified and upregulated in a variety of tumors, including hepatocellular tumors [35], ovarian carcinoma [36], colorectal carcinoma [37], and lung adenocarcinoma [38]. In addition, researches have demonstrated that FAM83D may act as a carcinogenic role by suppressing the invasion and proliferation of hepatocellular carcinoma and inhibiting the cell cycle of lung adenocarcinoma by suppressing FBXW7 in breast carcinoma [39–41]. These outcomes indicated that FAM83D may be widely taken part in process of tumors. Besides, FAM83D can advance epithelial-mesenchymal transition and metastasis of non-small cell lung carcinoma cells through the AKT/mTOR signal pathway, also improve the sensitivity of NSCLC cells to cisplatin [42]. Furthermore, FAM83D is highly expressed in invasive epithelial ovarian cancer and is related to tumor stage and grade [43]. Last but not least, FAM83D can also promote ovarian carcinoma cell invasion and proliferation, while suppressing autophagy through the PI3K/AKT/mTOR signaling pathway [44]. Therefore, we selected and tested whether microRNA-142-3p and FAM83D were differentially expressed in NOTs and OCTs. Besides, luciferase reporter assays verified that FAM83D was a direct target of miR-142-3p in OC cells. However, we need more cell experiments to prove it.

CONCLUSIONS

Our study indicated some reasons for the procession of OC. Plenty of DEMs and DEGs were selected between OC tissues and normal ovarian tissues. Besides, miR-142-3p and FAM83D were selected as latent biomarkers of OC. qPCR and IHC results indicated that microRNA-142-3p and FAM83D were differentially expressed in OC tissues. Besides, luciferase reporter assays verified that FAM83D was a direct target of miR-142-3p in OC cells. However, we need more cell experiments to prove it.

MATERIALS AND METHODS

Microarray data

The RNA-seq data of OC samples and corresponding normal ovarian tissues were retrieved from the GEO dataset (https://www.ncbi.nlm.nih.gov/geo/). The datasets of GSE81873 and GSE27651 were downloaded and divided into two groups.

Differently expressed miRNAs research

GEO2R is software for differential analysis of expression microarray based on the GEO database. Limma R package was used to identify DEGs in the construction cohort. The screening standards of DEGs for functional enrichment analysis were |log2FC|> 1 and FDR<0.05.

Gene ontology and pathway enrichment analysis

Transcription factors (TF), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Ontology (GO) enrichment analyses of the DEGs were performed by using R clusterProfiler package, including the package of “GOplot”, “ggplot2”, “stringr”, “colorscape” and “digest”. Then, the pathway and process enrichment analyses were carried out by using Cytoscape.
MicroRNA-mRNA regulatory network

At present, there are two generally recognized miRNA mechanisms: miRNA-mediated mRNA translation inhibition and miRNA-mediated mRNA-specific cleavage. In addition, researchers also found that miRNA may have other regulatory mechanisms, such as regulating the localization or stability of target mRNA, or acting on target molecules other than mRNAs, such as complementary binding with regulatory non-coding RNA or even miRNA, or competing with other RNAs to bind proteins to achieve its regulatory function. DEMs were uploaded to the FunRich software to achieve target mRNAs. Furthermore, GSE27651 was researched by utilizing R software. Based on the prediction conclusions of target mRNAs in FunRich software and the differentially expressed mRNAs of GSE27651, the microRNA-mRNA network was constructed.

The association between the expression level of identified genes and overall survival of patients with OC

Kaplan Meier plotter can assess the impact of 54K (mRNA, miRNA, protein) on the survival rate of 21 types of cancer (including breast cancer (n = 6234), ovarian cancer (n = 2190), lung cancer (n = 3452) and gastric cancer (n = 1440). The sources of the Kaplan Meier plotter database include GEO, EGA, and TCGA. The main purpose of the tool is the discovery and validation of survival biomarkers based on a meta-analysis. In this study, patients with OC were divided into two groups. By uploading the DEGs we identified, corresponding survival curves were obtained.

DEGs expression and clinical characteristics in the cancer genome atlas

The associated statistics offered by The Cancer Genome Atlas. The data of 1037 patients with ovarian cancer were downloaded in the TCGA database. The expression level of mRNAs, clinicopathological information, and general information of patients with OC were achieved.

Immunohistochemical staining

20 pairs of OC tissues were prepared by buffering with 10% formalin for 24 hours. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Soochow University and informed consent was obtained from all patients. 2 consecutive 5-m sections were taken from each formalin-fixed paraffin-embedded block and mounted on the glass slide treated with aminoalkyl silane, dewaxing with xylene, passing through graded alcohol, and then continue rinsing in deionized water and phosphate-buffered saline. It was blocked by 3% non-immune horse serum. The sections were incubated with broad-spectrum anti-cytokeratin AE1 / 3 (Dako, Santa Barbara, CA, USA) in 1:50 dilution overnight at room temperature. After washing twice in buffer, an appropriate biotinylated secondary antibody was applied for 30 minutes. After two more washes in the buffer, appropriate biotinylated secondary antibodies were applied for 30 minutes. The sections were developed under the microscope in Tris HCl buffer (pH 7.4) and 0.03% hydrogen peroxide for 20 minutes. Application of light Mayer hematoxylin. The expressions of FAM83D and β - Catenin were detected by the Chi-square test or Fisher exact test. GraphPad Prism 9 software was utilized for statistical analysis. P-value < 0.05 was considered statistically significant.

Real-time quantitative polymerase chain reaction

Total RNA was extracted from OC tissues and normal tissues by utilizing TRIzol reagents (Invitrogen, Carlsbad, CA, USA) as per the manufacturer’s instructions. The total RNA was reverse-transcribed into cDNA by utilizing a PrimeScript™RT kit with gDNA Eraser (TaKaRa, China). We also constructed Quantitative Real-time PCR (qRT-PCR) by using SYBR Select Master Mix for CFX (Invitrogen) and the CFX Connect Real-Time PCR System (BioRad). The amplification conditions are 95° C for 15s, then 40 cycles, 95° C for 5S, 60 ° C for the 30s. Primer sequences of FAM83D were as follows: primer F, 5' - GCACTTCCCTTTGTTGTA GTC −3', primer R, 5'-AGCACTTCCCTTAGG TTACTC −3'. Using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as endogenous control, the recorded data were analyzed and processed by 2−ΔΔCt.

Luciferase reporter assay

The relationship between miR-142-3p and FAM83D was verified by performing a luciferase reporter assay. To construct a luciferase ratio vector, we amplified the wild or mutant fragment FAM83D 3’-UTR containing the hypothetical binding site miR-142-3p and subcloned it into luciferase pLuc vector (Wuhan, Ruibo, China). OC cells were co-transfected with pLuc-FAM83D 3’-UTR wild (WT) or pLuc-FAM83D 3’-UTR (MU) mutants and miR-142-3p or NC analogues using Lipofoctamine 2000 according to the manufacturer’s instructions. After 48 hours of transfection, the relative activities of luciferase and double luciferase were detected by the analytical system (Promega, Madison, WI, USA). The luciferase activity of fireflies was normalized to Renilla luciferase activity.
Statistical methods

The data were expressed as mean ± standard error. All data analyses were performed using R software (version 3.6.6) and GraphPad Prism 9 software package (GraphPad Software, Inc., La Jolla, California, USA). The differences between the two addiction groups were compared by student’s t-test. All the experiments were made in triplicate.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Soochow University.

AUTHOR CONTRIBUTIONS

Conceptualization, Xiaofei Guo; Methodology, Guangyu Gao; Software, Wenyong Gu; Validation, Guangyu Gao; Formal Analysis, Guangyu Gao; Investigation, Yufeng Lu; Resources, Guangyu Gao; Data Curation, Guangyu Gao; Writing – Original Draft Preparation, Guangyu Gao; Writing – Review and Editing, Guangyu Gao; Visualization, Guangyu Gao; Supervision, Zhigang Chen; Project Administration, Zhigang Chen; Funding Acquisition, Zhigang Chen.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This study was approved by Pre-Research Project of the National Natural Science Foundation of China (SDFEYGJ2014); Suzhou Science and Technology Development Project (SYSD2019108); Science and Technology Program of Suzhou City (SLJ2021012).

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70:7–30. https://doi.org/10.3322/caac.21590 PMID:31912902
2. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019; 393:1240–53. https://doi.org/10.1016/S0140-6736(18)32552-2 PMID:30910306
3. Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, du Bois A, Vergote I, Reuss A, Bacon M, Friedlander M, Gallardo-Rincon D, Joly F, et al, and participants of the Fifth Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017; 28:727–32. https://doi.org/10.1093/annonc/mdw663 PMID:27993805
4. Kossai M, Leary A, Scoazec JY, Genestie C. Ovarian Cancer: A Heterogeneous Disease. Pathobiology. 2018; 85:41–9. https://doi.org/10.1159/000479006 PMID:29020678
5. Bushati N, Cohen SM. miRNA functions. Annu Rev Cell Dev Biol. 2007; 23:175–205. https://doi.org/10.1146/annurev.cellbio.23.090506.123406 PMID:17506695
6. Simonson B, Das S. MicroRNA Therapeutics: the Next Magic Bullet? Mini Rev Med Chem. 2015; 15:467–74. https://doi.org/10.2174/1389557515666150324123208 PMID:25807941
7. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010; 11:597–610. https://doi.org/10.1038/nrg2843 PMID:20661255
8. Tong J, Lu J, Yin Y, Wang Y, Zhang K. microRNA-195 Promotes Small Cell Lung Cancer Cell Apoptosis via Inhibiting Rap2C Protein-Dependent MAPK Signal Transduction. Technol Cancer Res Treat. 2020; 19:1533033820977546. https://doi.org/10.1177/1533033820977546 PMID:33302819
9. Wu Y, Shen Q, Chen X, Wu Y, Niu Y, Lv F. miR-1301-3p promotes the proliferation and migration of lung cancer cells via direct repression of polymerase I and transcript release factor. Oncol Lett. 2020; 20:286. https://doi.org/10.3892/ol.2020.12149 PMID:33014164
10. Katakura S, Kobayashi N, Hashimoto H, Kamimaki C, Tanaka K, Kubo S, Nakashima K, Teranishi S, Manabe S, Watanabe K, Horita N, Hara Y, Yamamoto M, et al. MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer. Thorac Cancer. 2020; 11:2975–82. https://doi.org/10.1111/1759-7714.13653 PMID:32893980
11. Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer. 2020; 122:943–52.
12. Thong MS, van Noorden CJ, Steindorf K, Arndt V. Cancer-Related Fatigue: Causes and Current Treatment Options. Curr Treat Options Oncol. 2020; 21:17. https://doi.org/10.1007/s11864-020-0707-5 PMID:32025928

13. Ballabio A. The awesome lysosome. EMBO Mol Med. 2016; 8:73–6. https://doi.org/10.15252/emmm.20150596 PMID:26787653

14. Pucino V, Cucchi D, Mauro C. Lactate transporters as therapeutic targets in cancer and inflammatory diseases. Expert Opin Ther Targets. 2018; 22:735–43. https://doi.org/10.1080/14728222.2018.1511706 PMID:30106309

15. Payen VL, Hsu MY, Rädecke KS, Wyart E, Vazeille T, Bouzin C, Porporato PE, Sonveaux P. Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter. Cancer Res. 2017; 77:5591–601. https://doi.org/10.1158/0008-5472.CAN-17-0764 PMID:28823732

16. Galli L, Marcelli G. [Water-electrolyte balances in urological surgery]. Arch Ital Urol Nefrol. 1968; 41:199–217. PMID:5737700

17. Xie Y, Shi X, Sheng K, Han G, Li W, Zhao Q, Jiang B, Feng J, Li J, Gu Y. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019; 19:783–91. https://doi.org/10.3892/mmr.2018.9713 PMID:30535469

18. Xu W, Yang Z, Lu N. A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adh Migr. 2015; 9:317–24. https://doi.org/10.1080/19336918.2015.1016686 PMID:26241004

19. Edirweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 2019; 59:147–60. https://doi.org/10.1016/j.semcancer.2019.05.012 PMID:31128298

20. Hamanaka D, Suzuki T, Kawanishi K, Sakamoto T, Yamazaki T, Odori T, Ishii Y, Torizuka K. Two cases of primary isolated chylopericardium diagnosed by oral administration of 131I-triolein. Radiat Med. 1983; 1:65–9. PMID:6093198

21. Hinz E. [Contribution to the standardization of experimental cisticercosis of the mouse as a model experiment for testing of agents effective against cysticercus]. Z Tropenmed Parasitol. 1965; 16:322–31. PMID:5885829

22. Dittrich M, Thomas AK, Stelma FF, Talla I, Niang M, Decam C, Sow S, Mbaye A, Gryseels B, Ehrich JH, Doehring E. Preliminary ultrasonographical observations of intestinal lesions in a community with heavy Schistosoma mansoni infection in Richard Toll, Senegal. Acta Trop. 1994; 58:331–6. https://doi.org/10.1016/0001-706x(94)90026-4 PMID:7709871

23. Ruckes J, Stalikamp B. [On an unusually large neurinoma of the lung]. Zentralbl Allg Pathol. 1967; 110:306–13. PMID:5303304

24. Watanabe M, Usui T, Shimizu M, Ito K, Okawara C. [Round table discussion; current status of the administrator of a nursing school and his problems]. Kango Kyoiku. 1968; 9:12–24. PMID:5187584

25. Mansoori B, Mohammadi A, Gjerstorff MF, Shirjang S, Asadzadeh Z, Khaze V, Holmskov U, Kazemi T, Dujif PH, Baradaran B. miR-142-3p is a tumor suppressor that inhibits estrogen receptor expression in ER-positive breast cancer. J Cell Physiol. 2019; 234:16043–53. https://doi.org/10.1002/jcp.28263 PMID:30741415

26. Hua S, Liu C, Liu L, Wu D. miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. Biochem Biophys Res Commun. 2018; 496:947–54. https://doi.org/10.1016/j.bbrc.2018.01.112 PMID:29360449

27. Gao J, Wu N, Liu X, Xia Y, Chen Y, Li S, Deng Z. MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1. Exp Ther Med. 2018; 15:5205–14. https://doi.org/10.3892/etm.2018.6107 PMID:29904404

28. Godfrey JD, Morton JP, Wilczynska A, Sansom OJ, Bushell MD. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Cell Death Dis. 2018; 9:644. https://doi.org/10.1038/s41419-018-0628-4 PMID:29844410

29. Lee YY, Yarmishyn AA, Wang ML, Chen HY, Chiou SH, Yang YP, Lin CF, Huang PI, Chen YW, Ma HI, Chen MT. MicroRNA-142-3p is involved in regulation of MGMT expression in glioblastoma cells. Cancer Manag Res. 2018; 10:775–85.
30. Li WQ, Zhao WC, Xin J, Niu TL, Chao YF, Zhou P, Zheng MH, Xu B. MicroRNA-142-3p suppresses cell proliferation and migration in bladder cancer via Rac1. J Biol Regul Homeost Agents. 2020. [Epub ahead of print]. https://doi.org/10.23812/19-460-A PMID:32107907

31. Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang H, Hong M, Jiang T, Jiang Q, Lu J, Huang X, Huang B. An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-α and cAMP/PKA pathways. Leukemia. 2012; 26:769–77. https://doi.org/10.1038/leu.2011.273 PMID:21979877

32. Isobe T, Hisamori S, Hogan DJ, Zabala M, Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS, Lam JS, Qian D, Dirbas FM, et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. Elife. 2014; 3:e01977. https://doi.org/10.7554/elife.01977 PMID:25406066

33. Gao X, Xu W, Lu T, Zhou J, Ge X, Hua D. MicroRNA-142-3p Promotes Cellular Invasion of Colorectal Cancer Cells by Activation of RAC1. Technol Cancer Res Treat. 2018; 17:1533033818790508. https://doi.org/10.1177/1533033818790508 PMID:30064309

34. Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, et al. The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001; 414:865–71. https://doi.org/10.1038/414865a PMID:11780052

35. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, Gorringe KL, Campbell IG. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One. 2010; 5:e9983. https://doi.org/10.1371/journal.pone.0009983 PMID:20386695

36. van Dekken H, Paris PL, Albertson DG, Alers JC, Andaya A, Kowbel D, van der Kwast TH, Pinkel D, Schröder FH, Vissers KJ, Wildhagen MF, Collins C. Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer. 2004; 39:249–56. https://doi.org/10.1002/gcc.20001 PMID:14732926

37. Yan L, Yao J, Qiu J. miRNA-495 suppresses proliferation and migration of colorectal cancer cells by targeting FAM83D. Biomed Pharmacother. 2017; 96:974–81. https://doi.org/10.1016/j.biopha.2017.11.138 PMID:29221726

38. Inamura K, Shimoji T, Ninomiya H, Hiramatsu M, Okui M, Satoh Y, Okumura S, Nakagawa K, Noda T, Fukayama M, Ishikawa Y. A metastatic signature in entire lung adenocarcinomas irrespective of morphological heterogeneity. Hum Pathol. 2007; 38:702–9. https://doi.org/10.1016/j.humpath.2006.11.019 PMID:17376511

39. Wang Z, Liu Y, Zhang P, Zhang W, Wang W, Curr K, Wei G, Mao JH. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. Oncotarget. 2013; 4:2476–86. https://doi.org/10.18632/oncotarget.1581 PMID:24344117

40. Liao W, Liu W, Liu X, Yuan Q, Ou Y, Qi Y, Huang W, Wang Y, Huang J. Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma. Oncotarget. 2015; 6:24132–47. https://doi.org/10.18632/oncotarget.4432 PMID:26125229

41. Shi R, Sun J, Sun Q, Zhang Q, Xia W, Dong G, Wang A, Jiang F, Xu L. Upregulation of FAM83D promotes malignant phenotypes of lung adenocarcinoma by regulating cell cycle. Am J Cancer Res. 2016; 6:2587–98. PMID:27904773

42. Yin C, Lin X, Wang Y, Liu X, Xiao Y, Liu J, Snijders AM, Wei G, Mao JH, Zhang P. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer. Cell Oncol (Dordr). 2020; 43:395–407. https://doi.org/10.1007/s13402-020-00494-9 PMID:32062523

43. Zhang Q, Yu S, Lok SI, Wong AS, Jiao Y, Lee LT. FAM83D promotes ovarian cancer progression and its potential application in diagnosis of invasive ovarian cancer. J Cell Mol Med. 2019; 23:4569–81. https://doi.org/10.1111/jcmm.14360 PMID:31037837

44. Zhu H, Diao S, Lim V, Hu L, Hu J. FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway. Acta Biochim Biophys Sin (Shanghai). 2019; 51:509–16. https://doi.org/10.1093/abbs/gmz028 PMID:30939187